SCHEMBL4010927

SCHEMBL4010927

O=c1cc(O)c2ccc3ccccc3c2[nH]1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 4/20 0.56
KDM4E B2RXH2 2/20 0.56
HPGD P15428 2/20 0.53
HTT P42858 2/20 0.53
SMN1; SMN2 Q16637 1/20 0.53
KIF11 P52732 1/20 0.49
MEN1 O00255 1/20 0.46
USP2 O75604 1/20 0.46
KMT2A Q03164 1/20 0.46
HSD17B10 Q99714 1/20 0.46
MCL1 Q07820 1/20 0.44
CSNK2A2 P19784 1/20 0.43
CSNK2B P67870 1/20 0.43
CSNK2A1 P68400 1/20 0.43
MPL P40238 1/20 0.41
CDC25A P30304 1/20 0.41
CDC25C P30307 1/20 0.41
PTPN22 Q9Y2R2 1/20 0.41
TRPM4 Q8TD43 1/20 0.41
NQO2 P16083 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16510570 0.79 KDM4E (0.61) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL30668529 0.78 KDM4E (0.62) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL852161 0.78 KDM4E (0.62) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL30171433 0.75 ALDH1A1 (0.59) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL2269012 0.74 KDM4E (0.64) ALDH1A1KDM4EHTTMEN1KMT2A
SCHEMBL14969300 0.74 KDM4E (0.53) ALDH1A1KDM4EMEN1KMT2AHSD17B10
SCHEMBL23530348 0.74 KIF11 (0.59) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL237720 0.74 CA12 (0.57) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL29871305 0.74 CA12 (0.57) ALDH1A1KDM4EHPGDHTTSMN1; SMN2
SCHEMBL30914261 0.72 KIF11 (0.75) ALDH1A1KDM4EHPGDHTTSMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7485649-B2 Inhibitors of checkpoint kinases MERCK & CO., INC. (US) 2009-02-03 US disclosed
US-20080214594-A1 Inhibitors Of Checkpoint Kinases MERCK SHARP & DOHME CORP. 2008-09-04 US disclosed
EP-1836807-A2 INHIBITORS OF CHECKPOINT KINASES Merck & Co., Inc. (US) 2007-09-26 EP disclosed
WO-2006074207-A2 INHIBITORS OF CHECKPOINT KINASES MERCK & CO., INC. (US) 2006-07-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080214594-A1 Inhibitors Of Checkpoint Kinases CHEK1, CHEK2, BUB1B ALDH1A1 3142/4885KDM4E 1025/4885HPGD 3439/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.